Industries > Pharma > Global Asthma & COPD Therapies Market 2017-2027

Global Asthma & COPD Therapies Market 2017-2027

Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs

PUBLISHED: 06 September 2017
PAGES: 300
PRODUCT CODE: PHA0234

Clear
WOOCS 2.2.1
SKU: PHA0234 Categories: , , Tags: ,

The global asthma & COPD therapies market was valued at $32.9bn in 2016 and is projected to grow at a CAGR of 5.6% in the first half of the forecast period. The Anti-inflammatory Drugs submarket will be the fastest growing submarket in the first half of the forecast period. This submarket is estimated to grow at a CAGR of 7.6%.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 300-page report you will receive 113 tables and 130 figures – all unavailable elsewhere.

The 300-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
Global Asthma & COPD Therapies Market forecasts from 2017-2027, further broken down into:
Global Asthma Therapies Market forecasts
Global COPD Therapies Market forecasts

Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
– Bronchodilators monotherapy
– Anti-inflammatory drugs
– Combination drugs

Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
Anti-leukotrienes: Singulair
Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

Revenue forecast for the Combination drugs market and the leading drugs:
– Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

• This report provides individual revenue forecasts from 2017-2027 for these regional and national markets:
– The US
– Japan
– EU5: Germany, France, UK, Italy, Spain
– BRIC: Brazil, Russia, India, China
– Mexico
– Other Countries

Global Asthma & COPD Therapies Market 2017-2027

• This report discusses the leading companies in the global asthma & COPD therapies market:
– GSK
– Boehringer Ingelheim
– AstraZeneca
– Novartis
– Merck
– Roche
– Teva

• This report discusses drugs currently in clinical development for treating asthma and COPD.

• This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.

Visiongain’s study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Global Asthma & COPD Therapies Market 2017-2027:
Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs
.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2017-2027


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories